Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22383790 | 0.88 | ACHE (0.43) | KMT2AESR1HIF1ASMN1; SMN2RECQL | |
| SCHEMBL17355711 | 0.86 | ACHE (0.58) | KMT2AESR1HIF1ASMN1; SMN2RECQL | |
| SCHEMBL1996155 | 0.86 | BCL9 (0.51) | KMT2AACHEALDH1A1KDM4EHSD17B10 | |
| SCHEMBL15763945 | 0.85 | KMT2A (0.42) | KMT2ASMN1; SMN2ACHEALDH1A1HPGD | |
| SCHEMBL28846397 | 0.84 | ACHE (0.49) | KMT2AESR1HIF1ASMN1; SMN2RECQL | |
| SCHEMBL27641267 | 0.84 | ESR1 (0.50) | KMT2AESR1HIF1ASMN1; SMN2RECQL | |
| SCHEMBL27714304 | 0.84 | ACHE (0.49) | KMT2AESR1HIF1ASMN1; SMN2RECQL | |
| SCHEMBL1999057 | 0.83 | MAPT (0.45) | KMT2ASMN1; SMN2RECQLALDH1A1KDM4E | |
| SCHEMBL3218515 | 0.83 | ACHE (0.48) | KMT2AESR1HIF1ASMN1; SMN2RECQL | |
| SCHEMBL6446983 | 0.83 | RARB (0.49) | KMT2AESR1HIF1ASMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-102516115-B | As the antagonist of Opioid Receptors or the new compound of inverse agonist | SMITHKLINE BEECHAN CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| CN-104112870-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEM CORP | 2014-10-22 | — | — | CN | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| CN-103980151-A | Novel compounds as antagonists or inverse agonists at opioid receptors | SMITHKLINE BEECHAM CORP | 2014-08-13 | — | — | CN | disclosed |
| CN-101522614-B | Compounds as antagonists or inverse agonists of opioid receptors | SMITHKLINE BEECHAM CORP | 2014-06-25 | — | — | CN | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| CN-101522614-A | Novel compounds as antagonists or inverse agonists of opioid receptors | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-2054383-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2049481-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| CN-101331120-A | Phenolic ether compounds as opioid receptor modulators | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | CN | disclosed |
| EP-1943226-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007047397-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | KMT2A 2191/4885ESR1 721/4885HIF1A 2798/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | KMT2A 3867/4885ESR1 453/4885HIF1A 2370/4885 |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | KMT2A 3694/4885ESR1 904/4885HIF1A 1523/4885 |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | KMT2A 3867/4885ESR1 453/4885HIF1A 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.